Nia Therapeutics

Nia TX is developing an AI-guided neurostimulation therapy for memory loss and has openings in neuroscience, engineering, data science, and other fields.

Nia TX's team has expertise in neuroscience, engineering, and AI and develops therapies to enhance memory and cognitive performance for patients with TBI.

Nia TX provides information about clinical trials, collaboration opportunities, and its Smart Neurostimulation therapy. It is based in Allston, MA.

Nia TX's Smart Neurostimulation System is a closed-loop brain-computer interface designed to address memory loss from traumatic brain injury using AI.

The Nia TX Privacy Policy describes how Nia TX collects, uses, and protects personal information.

Nia Therapeutics, co-founded by Michael Kahana and Dan Rizzuto, secures FDA **Breakthrough Device Designation** for its memory-restoration device targeting adult patients with traumatic brain injuries. The technology aims to address cognitive impairment by leveraging neuroscience research. The designation accelerates review for innovative medical devices addressing unmet needs.

Sep 2026Penn Center for InnovationNews article

Researchers advance toward developing an AI-driven device to address memory loss. The work builds on early collaborations, such as Michael Kahana’s 1990s presentation at Harvard Medical School, where he shared computer models of human memory with neurosurgery and neurology faculty. These foundational discussions may now inform next-generation therapeutic approaches.

Aug 2026Medical XpressNews article

Nia Therapeutics is preparing a first-in-human (FIH) clinical trial for its **Smart Neurostimulation System (SNS)**, the first implantable device granted **FDA Breakthrough Device Designation** for treating memory loss in patients with **moderate-to-severe traumatic brain injury (TBI)**. The system targets neurostimulation as a potential intervention for cognitive impairment following TBI. The trial follows the FDA’s approval of the device’s breakthrough status, accelerating its development path.

Mar 2026Medical Device NetworkNews article

Nia Therapeutics secures FDA Breakthrough Device Designation for its **Smart Neurostimulation System**, the first neurostimulation device targeting **traumatic brain injury (TBI)-related memory loss**. The implant analyzes neural activity across **60 channels in four brain regions** and delivers **AI-driven, personalized stimulation therapy** to the lateral temporal cortex. The designation accelerates development of this novel approach for memory restoration.

Mar 2026BioSpaceNews article